Corcept Therapeutics Incorporated Market Cap ($5.61 Billion)
Market Cap & Net Worth: Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated market cap. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $5.61 Billion ($5.61 Billion) as of November 6, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3227 globally and #1163 in its home market, demonstrating a -9.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corcept Therapeutics Incorporated's stock price $79.22 by its total outstanding shares 107351594 (107.35 Million). Also see Corcept Therapeutics Incorporated cash flow conversion for how efficiently the company converts equity into cash flow.
Corcept Therapeutics Incorporated Market Cap History (2015–2026)
Corcept Therapeutics Incorporated market cap history from 2015 to 2026. Data shows growth from $534.61 Million to $8.50 Billion (31.50% CAGR). Check Corcept Therapeutics Incorporated share price for real-time trading data and today's change.
Index Memberships
Corcept Therapeutics Incorporated is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.05 Trillion | 0.53% | #25 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.21% | #84 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.01% | #367 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.55 Trillion | 0.55% | #51 of 602 |
Weight: Corcept Therapeutics Incorporated's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corcept Therapeutics Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corcept Therapeutics Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Corcept Therapeutics Incorporated (CORT) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.91x
Corcept Therapeutics Incorporated's market cap is 4.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
37.49x
Corcept Therapeutics Incorporated's market cap is 37.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $779.37 Million | $81.32 Million | $8.14 Million | 9.58x | 95.75x |
| 2017 | $1.94 Billion | $159.20 Million | $129.12 Million | 12.18x | 15.02x |
| 2018 | $1.43 Billion | $251.25 Million | $75.41 Million | 5.71x | 19.02x |
| 2019 | $1.30 Billion | $306.49 Million | $94.18 Million | 4.24x | 13.79x |
| 2020 | $2.81 Billion | $353.87 Million | $106.01 Million | 7.94x | 26.49x |
| 2021 | $2.13 Billion | $365.98 Million | $112.51 Million | 5.81x | 18.89x |
| 2022 | $2.18 Billion | $401.86 Million | $101.42 Million | 5.43x | 21.50x |
| 2023 | $3.49 Billion | $482.38 Million | $106.14 Million | 7.23x | 32.85x |
| 2024 | $5.41 Billion | $675.04 Million | $139.73 Million | 8.01x | 38.71x |
| 2025 | $3.74 Billion | $761.41 Million | $99.65 Million | 4.91x | 37.49x |
Competitor Companies of CORT by Market Capitalization
Companies near Corcept Therapeutics Incorporated in the global market cap rankings as of November 6, 2026. Also see total assets of Corcept Therapeutics Incorporated for a full breakdown of the balance sheet.
Key companies related to Corcept Therapeutics Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Corcept Therapeutics Incorporated (2015–2026)
Market capitalization of Corcept Therapeutics Incorporated from 2015 to today. Between 2015 and today, Corcept Therapeutics Incorporated's market cap moved from $534.61 Million to $ 8.50 Billion, with a yearly change of 31.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.50 Billion | +127.64% |
| 2025 | $3.74 Billion | -30.94% |
| 2024 | $5.41 Billion | +55.14% |
| 2023 | $3.49 Billion | +59.92% |
| 2022 | $2.18 Billion | +2.58% |
| 2021 | $2.13 Billion | -24.31% |
| 2020 | $2.81 Billion | +116.20% |
| 2019 | $1.30 Billion | -9.43% |
| 2018 | $1.43 Billion | -26.02% |
| 2017 | $1.94 Billion | +148.76% |
| 2016 | $779.37 Million | +45.78% |
| 2015 | $534.61 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Corcept Therapeutics Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.61 Billion USD |
| MoneyControl | $5.61 Billion USD |
| MarketWatch | $5.61 Billion USD |
| marketcap.company | $5.61 Billion USD |
| Reuters | $5.61 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more